Skip to content

The signaling pathways in the therapeutic effects of GLP-1 on psotiasis in type 2 diabetes

The signaling pathways in the therapeutic effects of GLP-1 on psotiasis in type 2 diabetes

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015296
Enrollment
Unknown
Registered
2018-03-21
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes psoriasis

Interventions

Case series:For at least 3 months with lilac

Sponsors

Fuzhou General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) aged between 18 and 75 years, male and female; 2) according to the WHO standards (1999) in the diagnosis of type 2 diabetes, according to the diagnostic criteria of the journal of clinical dermatology at the same time, the typical erythema, silvery white scales, such as skin rash, confirmed by clinical and histopathologic examination psoriasis; 3) in the last 2 months before screening, drugs such as vitamin A acid, steroid hormones and immunosuppressive drugs were taken.

Exclusion criteria

Exclusion criteria: 1) T1DM; 2) pregnant and lactating patients; 3) history of malignant tumor; 4) serious heart, lung, kidney and liver diseases; 5) previous history of pancreatitis.

Design outcomes

Primary

MeasureTime frame
PASI;The inflammatory factors in serum are il-17, il-22, il-23, and tnf-a.;Inflammatory factors in skin tissues are il-17, il-22, il-23, and tnf-a;HE;Immunohistochemistry;

Countries

China

Contacts

Public ContactXu Xiangjin

Fuzhou General Hospital

xu98111@163.com+86 15695909128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026